Related Experiment Video
Updated: Apr 12, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
[Therapeutic options for brain metastases]
1Universitätsklinik für Innere Medizin, Comprehensive Cancer Center Vienna, Währinger Gürtel 18-20, 1090, Wien, Österreich, matthias.preusser@meduniwien.ac.at.
Abstract:
Brain metastases are common in cancer patients, especially in lung cancer, breast cancer and melanoma and represent a therapeutic challenge. Established local therapeutic procedures include neurosurgical resection, stereotactic irradiation and whole brain radiotherapy; however, for selected patients novel targeted therapies with documented activity against brain metastases are emerging. These include v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, the anticytotoxic T lymphocyte-associated protein 4 (CTL4A) antibodies ipilimumab in melanoma, HER2 antagonists in breast cancer and epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer. Therefore, the modern management of patients with brain metastases should be performed in an interdisciplinary setting and under consideration of relevant molecular markers to facilitate optimal patient outcome.
Insights
Brain metastases, common in lung cancer, breast cancer, and melanoma, present treatment challenges. Emerging targeted therapies and molecular markers are improving patient outcomes in an interdisciplinary setting.
Area of Science:
- Neuro-oncology
- Medical oncology
- Cancer therapeutics
Context:
- Brain metastases are a frequent complication in cancer patients, particularly those with lung cancer, breast cancer, and melanoma.
- Established treatments like surgery and radiotherapy have limitations.
- Emerging targeted therapies show promise for specific patient groups.
Purpose:
- To review the current landscape of brain metastases management.
- To highlight the role of novel targeted therapies.
- To emphasize the importance of molecular markers and interdisciplinary care.
Summary:
- Discusses the challenges in managing brain metastases.
- Details targeted therapies including BRAF inhibitors, ipilimumab (anti-CTL4A), HER2 antagonists, and EGFR/ALK inhibitors for specific cancers.
- Advocates for an interdisciplinary approach guided by molecular markers.
Impact:
- Improved patient outcomes through personalized, molecularly-guided treatment strategies.
- Highlights the evolving paradigm in brain metastases care.
- Facilitates better integration of novel therapies into clinical practice.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:14Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy